Amendment Serial No. 08/851,965 Page 3 of 20



1. (Three Times Amended) A method for treating or preventing gastritis in a subject in need thereof, comprising peripherally administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin or a CGRP.

2. (Three Times Amended) A method for treating or preventing gastric ulceration in a subject in need thereof, comprising peripherally administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin or a CGRP.

(Twice Amended) The method of claim 1, 2, 26, 30, or 31, further comprising administering a non-steroidal anti-inflammatory drug.

8. (Twice Amended) The method of claim 1, 2, 25, 26, 27, 28, 30, or 31, wherein said amylin agonist is 25,28,29 Pro-h-amylin [SEQ. ID. NO. 1].

(Once Amended) The method of claim 1 or 2, wherein said IC₅₀ of said amylin or amylin agonist is about 5 nM or less in a rat receptor binding assay.


2\ 19. (Once Amended) The method of claim 1, 2, 25, or 26, wherein said amylin or amylin agonist has an IC₅₀ of about 1 nM or less in a rat receptor binding assay.

Please cancel claims 17-18, without prejudice.

Please add new claims as follows:

3 --25. (New) A method of treating gastritis or gastric ulceration in a subject in need thereof by peripherally administering an amylin or an amylin agonist, wherein said amylin agonist is not a

Amendment Serial No. 08/851,965 Page 4 of 20



26. (New) A method of treating or preventing gastritis or gastric ulceration, which is induced by ethanol or a non-steroidal anti-inflammatory compound, in a subject in need thereof by peripherally administering an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin or a CGRP, and wherein said amylin or amylin agonist has an IC₅₀ of about 5 nM or less in a rat receptor binding assay.

(New) A method for treating or preventing gastritis in a subject, comprising: peripherally administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin or a CGRP; and administering a non-steroidal anti-inflammatory drug.

(New) A method for treating or preventing gastric ulceration in a subject, comprising: peripherally administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin or a CGRP; and administering a non-steroidal anti-inflammatory drug.

7 29. (New) A method according to claim 1, 2, 25, or 26, wherein the amylin or the amylin agonist has an IC₅₀ value in a rat receptor binding assay of less than about 50 pM.

30. (New) A method for treating gastritis in a subject, comprising peripherally administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin or a CGRP.

31. (New) A method for treating gastric ulceration in a subject, comprising peripherally administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin or a CGRP.--

Now My

Con.